Evotec SE (NASDAQ:EVO - Get Free Report)'s share price gapped down before the market opened on Wednesday . The stock had previously closed at $3.34, but opened at $3.19. Evotec shares last traded at $3.22, with a volume of 8,429 shares trading hands.
Evotec Stock Down 4.9 %
The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. The company's 50 day moving average price is $3.98 and its 200-day moving average price is $4.09.
Institutional Trading of Evotec
Hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP grew its stake in shares of Evotec by 29.7% during the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock worth $9,616,000 after acquiring an additional 602,858 shares during the period. Lighthouse Investment Partners LLC bought a new position in Evotec during the fourth quarter worth about $166,000. DCF Advisers LLC increased its stake in shares of Evotec by 5.9% in the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after purchasing an additional 12,816 shares in the last quarter. CSS LLC IL bought a new stake in shares of Evotec in the fourth quarter valued at approximately $50,000. Finally, Bank of America Corp DE lifted its stake in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after buying an additional 9,289 shares in the last quarter. 5.81% of the stock is currently owned by institutional investors.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
